首页> 外文期刊>Journal of Physiology and Biochemistry >hRpn13, a newly identified component of the 19S particle, regulates proliferation, differentiation, and function in the human osteoblast-like cell line MG63
【24h】

hRpn13, a newly identified component of the 19S particle, regulates proliferation, differentiation, and function in the human osteoblast-like cell line MG63

机译:hRpn13是19S颗粒的新鉴定成分,它调节人成骨样细胞系MG63的增殖,分化和功能

获取原文
获取原文并翻译 | 示例
           

摘要

The 26S proteasome is a key component of the ubiquitin-proteasome system, a process responsible for the majority of cellular protein degradation. The function of the proteasomal ubiquitin receptor hRpn13, a component of the 26S proteasome, is not completely understood. To investigate the role of hRpn13 in the ubiquitin-proteasome system in osteoblasts, the effects of suppressing and overexpressing the hRpn13 gene on proliferation, differentiation, and function of human osteoblast-like MG63 cells were examined. After knockdown of hRpn13 by small interfering RNA, changes in osteoblast proliferation were evaluated by methyl-thiazolyl-tetrazolium assay. There was an increase in markers for osteoblast proliferation, specifically alkaline phosphatase activity, and elevated protein levels of osteocalcin, proliferating cell nuclear antigen (PCNA), and ubiquitin. Furthermore, hRpn13 knockdown also resulted in a decrease in the ratio between the gene expressions of RANKL and OPG, key players in the pathogenesis of bone diseases that influence the normal balance between bone formation and resorption. In contrast, overexpression of hRpn13 inhibited the proliferation of MG63 cells, and decreased alkaline phosphatase activity as well as protein levels of osteocalcin, PCNA, and ubiquitin while the ratio of RANKL to OPG expression increased. To confirm the function of hRpn13 in the ubiquitin-proteasome pathway, osteoblast proliferation enhancement and ubiquitin accumulation after hRpn2 knockdown was assessed. The results suggest that overexpression of hRpn13 negatively influences proliferation and osteogenic differentiation in MG63 cells. The evidence implies that hRpn13 modulates the influence of osteoblasts on osteoclasts by controlling the stability of regulatory proteins in osteoblasts. In summary, overexpression of hRpn13 promoted the activity of the ubiquitin-proteasome system.
机译:26S蛋白酶体是泛素-蛋白酶体系统的关键组成部分,该过程负责大多数细胞蛋白质的降解。蛋白酶体泛素受体hRpn13(26S蛋白酶体的组成部分)的功能尚未完全了解。为了研究hRpn13在成骨细胞中泛素-蛋白酶体系统中的作用,研究了抑制和过度表达hRpn13基因对人成骨样MG63细胞增殖,分化和功能的影响。用小干扰RNA敲低hRpn13后,通过甲基噻唑基-四唑鎓分析评估成骨细胞增殖的变化。成骨细胞增殖的标志物,特别是碱性磷酸酶活性,以及​​骨钙素,增殖性细胞核抗原(PCNA)和泛素的蛋白质水平升高,都有增加。此外,hRpn13基因敲低还导致RANKL和OPG基因表达之间的比率降低,而RANKL和OPG是影响骨骼形成和吸收正常平衡的骨骼疾病发病机理中的关键角色。相反,hRpn13的过表达抑制了MG63细胞的增殖,并降低了碱性磷酸酶的活性以及骨钙素,PCNA和泛素的蛋白质水平,而RANKL与OPG表达的比率却增加了。为了确认hRpn13在泛素-蛋白酶体途径中的功能,评估了hRpn2敲低后成骨细胞的增殖增强和泛素积累。结果表明hRpn13的过度表达对MG63细胞的增殖和成骨分化产生负面影响。有证据表明,hRpn13通过控制成骨细胞中调节蛋白的稳定性来调节成骨细胞对破骨细胞的影响。总之,hRpn13的过表达促进了泛素-蛋白酶体系统的活性。

著录项

  • 来源
    《Journal of Physiology and Biochemistry》 |2012年第1期|p.129-139|共11页
  • 作者单位

    State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, 14 Renminnan Road, Chengdu, Sichuan, 610041, China;

    State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, 14 Renminnan Road, Chengdu, Sichuan, 610041, China;

    State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, 14 Renminnan Road, Chengdu, Sichuan, 610041, China;

    Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China;

    State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, 14 Renminnan Road, Chengdu, Sichuan, 610041, China;

    Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China;

    School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    hRpn13; Proliferation; Differentiation; Kappa-B ligand; Osteoprotegerin; MG63; Osteoblast;

    机译:hRpn13;增殖;分化;κB配体;骨轮蛋白;MG63;成骨细胞;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号